Moderate to Severe Hypertension Completed Phase 3 Trials for Aliskiren (DB09026)

IndicationStatusPhase
DBCOND0042937 (Moderate to Severe Hypertension)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00841672Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe HypertensionTreatment